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Abstract
Background: Stargardt’s disease (STGD) and Retinitis Pigmentosa (RP) are inherited retinal degenerations that may
be affected, in opposite way, by diet.
Methods: Dietary profile was assessed in 24 patients with STGD and in 56 patients with RP. We documented in
only 6 out of 24 (25 %) STGD patients a daily intake of vitamin A within the recommended range while 14/24
(58.3 %) reported a high daily intake and 4/24 (16.7 %) showed a low daily intake. With regard to RP, 4/56 (7.1 %)
reported to be within the recommended range, 37/56 (66.1 %) reported high daily intake and 15/56 (26.8 %)
showed low daily intake of vitamin A.
Results: Interestingly, STGD patients with low vitamin A intake (<600 µg RAE/day) showed significantly better visual
acuity with respect to those introducing higher intake of vitamin A.
Conclusion: The present study suggests insuitable nutrient intakes among patients with STGD and RP, especially
for daily intake of vitamin A. The results may be used to provide tailored nutritional interventions in these patients.
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Background
Vitamin A plays a crucial role in the biochemistry of vis-
ual signal cascade and the maintenance of an optimal
vitamin A status has been considered relevant for a nor-
mal retinal physiology [1, 2].
Stargardt’s Disease (STGD) and Retinitis Pigmentosa
(RP) are genetic-based relevant ocular diseases that may
be affected, in opposite way, by vitamin A intake and
other nutrients [3–5].
In an animal model of STGD vitamin A supplementa-
tion has been shown to accelerate the accumulation of
toxic by-products, being prevented by a reduction of its
serum levels with possible implications for the treatment
[6]. Moreover, in such patients a supplementation with
lutein, a retinal carotenoid, increases macula pigment
density but it seems not to be associated with changes in
central vision over a 6 months-follow up period [7].
Conversely, RP patients seems to get beneficial effects
from a supplementation with vitamin A, since it has
been associated with an improved preservation of cone
electroretinogram amplitudes and has been proposed as
a treatment to slow the progression of the disease [8].
Moreover, for RP patients assuming vitamin A therapy
addition of the polyunsaturated fatty acid docosahexae-
noic acid has been showed to slow the course of the dis-
ease over the first two years of supplementation [9–11].
Similarly, an increased dietary intake of lutein, a retinal
carotenoid, seems to slow visual function loss in RP
adult patients assuming vitamin A [12]. In the light of
all these clinical observations, nutritional indications
and/or supplementations for patients suffering from
these retinal dystrophies are usually given but, to the
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best of our knowledge, no data on dietary habits of these
patients are presently available.
The purpose of this study was to evaluate the dietary
habits and nutritional intake of vitamin A in patients
with STGD and RP, in order to suggest tailored dietary
modifications in such diseases.
Methods
Study population
The study populations comprised 24 patients with a
STGD [12 M, 12 F; median age: 34 years (range: 13–64)]
and 56 patients with RP [23 M, 33 F; median age:
45 years (range: 14–85)] referring to the Eye Clinic of
the University of Florence, Italy for clinical evaluation.
For patients under 18 years of age, the informed consent
was obtained from their parents.
The criteria for STGD phenotype included the follow-
ing: appearance in the first or second decade of life; bi-
lateral progressive central vision loss; macular atrophy/
dystrophy; normal calibre of retinal vessels; absence of
pigmented bone spicules; and normal or mildly abnor-
mal full-field electroretinogram. Flecks at the posterior
pole and dark choroid at fluorescein angiography were
present in most of the cases but their absence was not
considered an exclusion criterion. All the patients car-
ried bi-allelic mutations of the ABCA4 gene [13, 14].
The clinical diagnosis of RP was based on the history of
night blindness, typical retinal pigmentary changes, at-
tenuated retinal vessels, reduced or absent electroretino-
gram response and progressive peripheral visual field
loss. For these patients the molecular analysis could not
be performed.
Figure 1 illustrates a typical STGD while Fig. 2 shows
the fundus appearance of a classic RP.
All the patients included in the study were clinically
evaluated by means of a standard ophthalmologic examin-
ation, electroretinography (Electrophysiological Diagnostic
Unit Retimax, Roland Consult, Brandenburg, Germany)
performed according to the existing ISCEV Guidelines,
OCT scan (Topcon 3D OCT-1000, Topcon Medical
Systems Inc, Oakland, NJ, USA) and automated visual
field examination (Humprey Automated Perimeter, Carl
Zeiss, Dublin, CA, USA). Fluorescein angiography (Zeiss
Retinograph with Image Processing Software Visupac,
Carl Zeiss, Dublin, CA, USA) was obtained in 15 STGD
patients either to refine the diagnosis or to investigate the
possible presence of dark choroid.
In both groups age of onset of the visual symptoms
and visual acuity at the time of the dietary analysis were
considered as possible markers of disease severity. The
study adhered to the tenets of the Declaration of
Helsinki and was approved by the AOU Careggi Ethics
Committee. Each patient gave written informed consent.
Dietary analysis
Trained dieticians collected data in order to assess the
habitual consumption of 109 food items, with the aid of
software specific for the analysis of food habits and the
estimation of nutrient and caloric intake (WinFood, re-
lease 1.5; Medimatica, Martinsicuro, Te, Italy). For each
specific food item a commonly used portion size was
specified and subjects were asked how often they had
consumed that unit (never, daily, weekly, monthly) on
average during the past year. Emphasis was paid to en-
sure that the answers were related to a yearlong dietary
pattern and not to last few months, especially in terms
of seasonal changes of diet. Nutrient intakes were pre-
sented for comparison with the dietary reference intakes
(RDI) for males and females aged 18–59 years [15].
Statistical analysis
Statistical analysis was performed by using the SPSS
(Statistical Package for Social Sciences Inc., Chicago, IL,
USA) software for Macintosh (Version 19.0). Values are
expressed as mean ± standard deviation (SD) or median
and range, as appropriate. Chi-square test was used to
test for proportions. T-test was used for comparisons be-
tween single groups for normally distributed parameters
and Mann–Whitney test was used for comparison of age
between groups. A p-value <0.05 was considered to indi-
cate statistical significance.
Results
Clinical characteristics
The median age at onset of symptoms was 20.5 years
(range: 8–39) for STGD and 30 years (range: 2–72) for
RP, with the median duration of the disease of 11.5 years
(range: 0–39) and 14 years (range: 0–53) for STGD and
RP, respectively.
At the moment of the dietary analysis Snellen equiva-
lent visual acuity was 3.8 ± 3.1 in the right eye and 3.8 ±
Fig. 1 STGD: macular atrophy and flecks at the posterior pole
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3.2 in the left eye for STGD as compared to 5.4 ± 3.8 in
the right eye and 5.1 ± 3.7 in the left eye for RP patients.
Dietary profile
Dietary pattern of the study population is described in
Tables 1 and 2, for STGD and RP respectively. Macronu-
trient distributions were not significantly different be-
tween males and females for both groups of patients. By
comparing the dietary patterns with the dietary reference
intakes reported by the Italian Society of Human Nutri-
tion (Italian Society of Human Nutrition, [15]) in order
to prevent the major chronic diseases we can observe
some divergences from the recommendations. Indeed, in
both males and females the study populations showed a
slightly increased contribution of total fat from the diet,
with a considerably low contribution from polyunsatur-
ated fats. In addition, a low intake of fibre is showed in
both genders of the two groups of patients as well as a
high intake of cholesterol was demonstrated in all the
patients.
As considering minerals and vitamins, both groups of
patients reported insufficient intake of some minerals
and vitamins, as showed by low intake of calcium, mag-
nesium, potassium, vitamin B6, folic acid and vitamin D.
In Table 3, prevalence of patients following recom-
mendations for a healthy diet is reported. Notably, a
high proportion of patients consume a hyperlipidic
diet with a contribution from total fat >30 % of the
total energy in 19/24 (79.2 %) STGD and 45/56 (80.4 %)
RP patients. More importantly, almost the total number
of patients enrolled in the study showed an insufficient
intake for polyunsaturated fats, and a high proportion
of the patients reported a high intake of cholesterol
from the diet. Similarly, almost the totality of the pa-
tients did not reach current recommendations for
fibre intake.
Vitamin A and other nutrients
With regard to vitamin A intake, only 6 out of 24 STGD
patients (25 %) reported a daily intake of vitamin A that
follows the recommendations for a healthy diet (Table 3
and Fig. 3). Contrarily to what suggested for patients
with such disease, interestingly, in 14/24 (58.3 %) a high
intake of vitamin A from the diet was reported. In this
group of patients the average intake of dietary vitamin A
was 1329.8 µg RAE/day (SD: 828.4) with a range of
706.3–3863.2 µg RAE/day, and one patient exceeded the
upper toxicity level (3000 µg RAE/day). Looking at the
clinical characteristics, it came evident that such patient
presented with a very low visual acuity (right eye: 1.0;
left eye: 1.2) and an early age of onset of the disease
(19 years). Similarly, as far as RP is concerned, only 4
out of 56 patients (7.1 %) reported to meet the current
recommendations for daily intake of vitamin A from the
diet. Even in this group of patients, contrarily to what
usually recommended by physicians, a relatively high
proportion of patients, i.e., 15/56 (26.8 %) reported to
consume a low intake of vitamin A (<600 µg RAE/day)
(Fig. 3).
Interestingly, STGD patients with low vitamin A in-
take (<600 µg RAE/day) showed significantly better vis-
ual acuity (right eye: 6.8 ± 3.4; left eye: 7.0 ± 3.8 vs. 3.2 ±
2.8 and 3.2 ± 2.7; p = 0.04) with respect to those introdu-
cing higher intake of vitamin A (>700 µg RAE/day). On
the other hand, RP patients with high vitamin A intake
(>700 µg RAE/day) showed a higher, albeit not
Fig. 2 RP: Pale optic disc, attenuated retinal vessels, midperipheral dystrophy of the retinal pigment epithelium with typical pigmentary changes
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significant, age of onset of the disease (30.8 ± 5.7 years)
vs. those reporting low vitamin A intake (25.5 ±
9.0 years).
Finally, intake of EPA and DHA from diet was also
evaluated. Among STGD patients, 10 out of 24 (41.7 %)
patients reported not to reach the recommendations for
these relevant nutrients (>250 mg/day). A similar result
has been reported in the RP group since 17 out of 56
(30.4 %) patients showed not to reach the current rec-
ommendations for the introduction of EPA +DHA with
the diet.
Discussion
Over the last years, some nutrients like vitamin A, doco-
sahexaenoic acid, and lutein have been proposed to in-
fluence the clinical course of the two most common
retinal dystrophies, STGD and RP [8, 9, 12]. In fact in
STGD vitamin A cannot be properly metabolized
because of ABCA4 protein impairment and gives origin
to toxic byproducts which are the main components of
lipofuscin [2, 6]. On the other side in most RP patients
genetic abnormalities prevent the appropriate processing
of vitamin A in phototransduction and visual cycle
[2, 4, 5, 16]. Indeed, in opposite ways, both STGD
and RP may be significantly influenced by dietary in-
take of these nutrients.
In STGD, experimental studies in animal models sug-
gested that a reduction of vitamin A dietary intake, and
their resulting circulating levels, might arrest the accu-
mulation of retinal toxic metabolites, so ameliorating the
clinical course of the disease [17]. However, a low vita-
min A diet has never been proposed and evaluation of
dietary profiles of these patients has never been con-
ducted. Conversely, in RP, nutritional supplementation
with vitamin A associated with docosahexaenoic acid or lu-
tein has been already evaluated in clinical trials [8, 10, 12],
Table 1 Dietary profile and nutrient intake in patients with Stargardt’s Disease
Males (n = 12) Females (n = 12)
Mean (SD) DRI Mean (SD) DRI
Energy, kcal 2249.9 (309.4) 2200 1773 (338.2) 1800
% of energy from carbohydrates 51.3 (4.4) 45–60 % 52.4 (7.9) 45–60 %
% of energy from protein 15.6 (1.8) 15–20 % 15.8 (2) 15–20 %
% of energy from fats 33.2 (5) <30 % 34.8 (7.3) <30 %
% of energy from saturated fats 8.7 (2.3) <10 % 9.8 (3) < 10 %
% of energy from monounsaturated fats 15.3 (2.7) 15–20 % 14.9 (4.7) 15–20 %
% of energy from polyunsaturated fats 3.4 (0.6) 5–10 % 3.5 (0.9) 5–10 %
EPA, mg 230 (130) >250 120 (70) >250
DHA, mg 290 (70) 130 (90)
Cholesterol, mg 286.7 (104.8) <200 209.5 (56.9) <200
Dietary fibre, g 18.5 (4.3) 25 16.3 (4.6) 25
Calcium, mg 707.3 (250.6) 1000 615.9 (220.8) 1000
Magnesium, mg 146.4 (32.1) 240 130.9 (26.3) 240
Potassium, mg 2394.8 (767.1) 3900 2225.3 (495.5) 3900
Sodium, mg 1462.3 (606) 1500 1476.2 (832.2) 1500
Iron, mg 10.2 (1.7) 10 13.5 (2.3) 18
Vitamin A, μg RAE 1277.9 (962.8) 700 729.4 (258.8) 600
Thiamin, mg 1.23 (0.25) 1.2 1.19 (0.32) 1.1
Riboflavin, mg 1.56 (0.47) 1.6 1.16 (0.32) 1.3
Niacin, mg 16.9 (2.4) 18 13.9 (2.9) 18
Vitamin B6, mg 1.14 (0.43) 1.3 1.17 (0.53) 1.3
Folic acid, mg 193.2 (100.3) 400 201.5 (80.9) 400
Vitamin C, mg 161.7 (103.6) 105 136.2 (73.8) 85
Vitamin D, μg 3.41 (1.71) 15 2.33 (1.65) 15
Vitamin E, mg 11.1 (3.5) 15 7.92 (3.7) 15
The dietary reference intakes (DRI) are presented using adequate intake and population reference intake for males and females aged 18–59 years according to the
Dietary Reference Values of the Italian Society of Human Nutrition [15]
EPA eicosapentaenoic acid, DHA docosahexaenoic acid, RAE retinol activity equivalent
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Table 2 Dietary profile and nutrient intake in patients with Retinitis Pigmentosa
Males (n = 23) Females (n = 33)
Mean (SD) DRI Mean (SD) DRI
Energy, kcal 1994.9 (436.4) 2200 1830 (362.1) 1800
% of energy from carbohydrates 47.9 (7.9) 45–60 % 49.6 (6.2) 45–60 %
% of energy from protein 16.7 (2.6) 15–20 % 17.7 (2.8) 15–20 %
% of energy from fats 34.6 (6.2) <30 % 34.1 (5.6) <30 %
% of energy from saturated fats 9.3 (2.8) < 10 % 9.3 (2.3) < 10 %
% of energy from monounsaturated fats 15.6 (3.6) 15–20 % 15 (3.7) 15–20 %
% of energy from polyunsaturated fats 3.6 (1) 5–10 % 3.4 (0.9) 5–10 %
EPA, mg 180 (130) >250 230 (60) >250
DHA, mg 190 (150) 280 (60)
Cholesterol, mg 284.4 (113.9) <200 266.3 (87.6) <200
Dietary fibre, g 15.5 (4.5) 25 15.9 (4.3) 25
Calcium, mg 596.9 (198.8) 1000 662.5 (213.9) 1000
Magnesium, mg 138.8 (50.4) 240 139.6 (33.6) 240
Potassium, mg 2432.8 (511.5) 3900 2423.9 (552.5) 3900
Sodium, mg 1626.8 (563.1) 1500 1357.8 (443.1) 1500
Iron, mg 11.7 (3.7) 10 10.9 (2.8) 18
Vitamin A, μg RAE 1332.9 (205.7) 700 1368.9 (498.7) 600
Thiamin, mg 1.07 (0.35) 1.2 1.05 (0.21) 1.1
Riboflavin, mg 1.56 (0.47) 1.6 1.16 (0.32) 1.3
Niacin, mg 17.3 (5.4) 18 15.4 (4.9) 18
Vitamin B6, mg 1.26 (0.43) 1.3 1.33 (0.39) 1.3
Folic acid, mg 203.9 (80.4) 400 221.2 (66.8) 400
Vitamin C, mg 112.1 (60.6) 105 136.3 (50.5) 85
Vitamin D, μg 3.83 (2.76) 15 4.44 (2.24) 15
Vitamin E, mg 9.7 (3.6) 15 9.2 (3.1) 15
The dietary reference intakes (DRI) are presented using adequate intake and population reference intake for males and females aged 18–59 years according to the
Dietary Reference Values of the Italian Society of Human Nutrition [15]
EPA eicosapentaenoic acid, DHA docosahexaenoic acid, RAE retinol activity equivalent
Table 3 Prevalence of men and women following the dietary reference intake (DRI) for selected nutrients
Stargardt’s disease Retinitis pigmentosa
Males (n = 12) Females (n = 12) Males (n = 23) Females (n = 33)
Carbohydrates (45–60 % TE), n (%) 11 (91.7) 7 (58.3) 13 (56.5) 23 (69.7)
Protein (15–20 % TE), n (%) 7 (58.3) 7 (58.3) 14 (60.9) 22 (66.7)
Fats (<30 % TE), n (%) 2 (16.7) 3 (25) 5 (21.7) 6 (18.7)
SFA (<10 % of total fats), n (%) 8 (66.7) 7 (58.3) 15 (65.2) 19 (57.6)
MUFA (15–20 % of total fats), n (%) 8 (66.7) 5 (41.7) 10 (43.5) 15 (45.5)
PUFA (5–10 % of total fats), n (%) 0 (0) 0 (0) 1 (4.3) 0 (0)
Cholesterol (<200 mg), n (%) 3 (25) 6 (50) 5 (21.7) 8 (24.2)
Dietary fibre (>25 g), n (%) 0 (0) 0 (0) 0 (0) 1 (3)
Vitamin A (600–700 μg RAE), n (%) 1 (8.3) 5 (41.7) 2 (8.7) 2 (6.1)
EPA + DHA (>250 mg), n (%) 10 (83.3) 4 (33.3) 15 (65.2) 24 (72.7)
DRIs for the selected macronutrient or nutrient are reported in brackets
STGD Stargardt’s Disease, PR pigmentosa retinitis, TE total energy, SFA saturated fats, MUFA monounsaturated fats, PUFA polyunstaurated fats, EPA
eicosapentaenoic acid, RAE retinal activity equivalent, DHA docosahexaenoic acid
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showing some beneficial effects, even if the efficacy and
safety of this approach is still controversial: in fact, the high
doses of vitamin A proposed in RP patients have the
potential risk of bone and liver damage, and severe birth
defects if assumed by pregnant women [18].
In our study we investigated the dietary habits of some
patients affected by RP or STGD in order to seek for
possible tailored dietary intervention to suggest to these
patients. The study population showed some divergences
from nutritional recommendations that may be cor-
rected through a nutritional intervention. Indeed, a high
proportion of patients consume a hyperlipidic diet with
a high assumption of cholesterol and a low intake of
polyunsaturated fatty acids and fibre. Interestingly, with
regard to vitamin A intake, we reported that the daily in-
take of vitamin A in STGD patients was higher than
what recommended in a relevant portion of the study
population. In this group of patients, the high intake of
vitamin A was also associated with a worst clinical
course of the disease in terms of visual acuity. Con-
versely, in RP patients vitamin A intake was lower than
dietary recommendations in a relevant percentage of RP
patients, with a resultant - even if not significant - worst
clinical profile in terms of earlier age of onset of the dis-
ease. These data, showing a relevant prevalence of insui-
table nutrient intakes among our patients with retinal
dystrophies, supports the possible influence of diet on
the pathogenesis of some inherited retinal degenerations
and suggests a nutritional intervention in these patients.
Actually, the dietary pattern of these patients may play
a significant role in the clinical course of the disease and
may represent a therapeutic approach for disorders pres-
ently without effective treatment.
The study has some limitations. First, the small sample
size of the study population does not allow us to establish
possible relationships between nutrients and different clin-
ical features of the retinal degenerations. On the other
hand, it should be noted that STGD is a relatively rare
condition and this is the first study investigating this issue.
Second, the nature of the study i.e., cross-sectional design
does not give us the opportunity to confirm a causal rela-
tionship between nutritional and clinical characteristics of
these diseases. Moreover RP and STGD may show a very
high phenotypic variability and so the association between
nutrients intake and clinical course must be considered
not conclusive. Third, circulating levels of vitamin A could
not be measured in such patients. The measurements of
serum vitamin A levels would have improved the know-
ledge of the pathophysiological mechanisms at the
basis of the onset and of the grade of severity of the
disease. Finally the possible influence of multiple lifestyle
features (like smoking, drugs assumption, BMI) should be
considered in future investigations.
Conclusions
Nevertheless, despite all these limitations, the strength
of the present study is that it is the first study that evalu-
ated the dietary profile of patients with retinal dystro-
phies. The altered intake of many nutrients in the diet of
these patients supports the idea that a nutritional inter-
vention can be attempted before giving a prescription
with nutritional supplementations. Further studies are
requested to evaluate the balance between the possible
clinical benefits of a reduced vitamin A intake and the
potential ocular (night blindness and xerophthalmia)
and systemic (depression, skin problems and others) risk
of vitamin A deficiency.
Abbreviations
RAE: retinal activity equivalent; RP: Retinitis Pigmentosa; STGD: Stargardt’s
disease.
Competing interests
All authors declare that there are no competing interest.
Fig. 3 Prevalence of STGD and RP patients according to dietary recommendations of vitamin A
Sofi et al. BMC Ophthalmology  (2016) 16:13 Page 6 of 7
Authors’ contributions
Conception and design: FS, AC, AS. Analysis and interpretation of the data:
FS, VM, AM, GA, FF, AS. Drafting of the article: FS, FF, RA, GFG, UM, AC, AS
Dietary analysis: FS, AC, DB. Clinical evaluation of patients: AS, VM, AM, GA.
Critical revision of the article for important intellectual content: RA, GFG, UM,
AC. Final approval of the article: FS, FF, RA, GFG, UM, AC, AS. Statistical
expertise: FS.
Financial disclosure
Nothing to declare
Author details
1Department of Experimental and Clinical Medicine, University of Florence,
Florence, Italy. 2Agency of Nutrition, University Hospital of Careggi, Florence,
Italy. 3Don Carlo Gnocchi Foundation Italy, Onlus IRCCS, Florence, Italy.
4Department of Surgery and Translational Medicine, Eye Clinic, University of
Florence, Florence, Italy.
Received: 16 February 2015 Accepted: 8 January 2016
References
1. Lien EI, Hammond BR. Nutritional influences on visual development and
function. Progr Ret Eye Res. 2011;30:188–203.
2. Palczewski K. Chemistry and Biology of Vision. J Biol Chem. 2012;287:1612–9.
3. Chappelow AV, Traboulsi EI. Stargardt Disease. In: Traboulsi EI, editor.
Genetic Diseases of the Eye. Oxford-New York: Oxford University Press;
2012. p. 467–75.
4. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet. 2006;368:
1795–809.
5. Ferreyra HA, Heckenlively JR. Retinitis Pigmentosa. In: Traboulsi EI, editor.
Genetic Diseases of the Eye. Oxford-New York: Oxford University Press;
2012. p. 381–92.
6. Radu RA, Yuan Q, Hu J, Peng JH, Lloyd M, Nusinowitz S, et al. Accelerated
accumulation of lipofuscin pigments in the RPE of a mouse model for
ABCA4-mediated retinal dystrophies following Vitamin A supplementation.
Invest Ophthalmol Vis Sci. 2008;49:3821–9.
7. Aleman TS, Cideciyan AV, Windsor EA, Schwartz SB, Swider M, Chico JD, et
al. Macular pigment and lutein supplementation in ABCA4-associated retinal
degenerations. Invest Ophthalmol Vis Sci. 2007;48:1319–29.
8. Berson EL, Rosner B, Sandberg MA, Hayes KC, Nicholson BW, Weigel-
DiFranco C, et al. A randomized trial of vitamin A and vitamin E
supplementation for retinitis pigmentosa. Arch Ophthalmol. 1993;111:761–
72.
9. Berson EL, Rosner B, Sandberg MA, Moser A, Brockhurst RJ, Hayes KC, et al.
Clinical trial of docosohexanoic acid in patients with Retinitis Pigmentosa
receiving vitamin A treatment. Arch Ophthalmol. 2004;122:1297–305.
10. Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Moser A, Brockhurst
RJ, et al. Further evaluation of docosohexanoic acid in patients with Retinitis
Pigmentosa receiving vitamin A treatment. Arch Ophthalmol. 2004;122:
1306–14.
11. Berson EL, Rosner B, Sandberg MA, Weigel-Di Franco C, Willett W. ω-3 intake
and visual acuity in patients with Retinitis Pigmentosa receiving vitamin A.
Arch Ophthalmol. 2012;130:707–11.
12. Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Brockhurst RJ, Hayes KC,
et al. Clinical trial of lutein in patients with Retinitis Pigmentosa receiving
vitamin A. Arch Ophthalmol. 2010;128:403–11.
13. Koenekoop RK. The gene for Stargardt disease, ABCA4, is a major retinal
gene: a mini-review. Ophthalmic Genet. 2003;24:75–80.
14. Passerini I, Sodi A, Giambene B, Mariottini A, Menchini U, Torricelli F. Novel
mutations of the ABCR gene in Italian patients with Stargardt Disease. Eye.
2010;24:158–64.
15. Italian Society of Human Nutrition. Livelli di Assunzione di Riferimento
di Nutrienti ed energia per la popolazione italiana 2012. Available at:
http://www.sinu.it/html/pag/larn-2014.asp (accessed on August, 28 2013).
16. Perusek L, Maeda T. Vitamin A derivatives as treatment options for retinal
degenerative diseases. Nutrients. 2013;5:2646–66.
17. Radu RA, Han Y, Bui TV, Nusinowitz S, Bok D, Lichter J, et al. Reductions in
serum vitamin A arrest accumulation of toxic retinal fluorophores: a
potential therapy for
treatment of lipofuscin-based retinal diseases. Invest Ophthalmol Vis Sci.
2005;46:4393–401.
18. Massof RW, Fishman GA. How strong is the evidence that nutritional
supplements slow the progression of Retinitis Pigmentosa? Arch
Ophthalmol. 2010;128:493–5.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Sofi et al. BMC Ophthalmology  (2016) 16:13 Page 7 of 7
